Searchable abstracts of presentations at key conferences in endocrinology

ea0077p43 | Metabolism, Obesity and Diabetes | SFEBES2021

5β-reductase is downregulated in patients with non-alcoholic fatty liver disease and hepatocellular carcinoma and controls metabolic and proliferative phenotype through LXR-dependent mechanisms

Nikolaou Nikolaos , Arvaniti Anastasia , Sanna Fabio , Saikali Michael , da Conceicao Ismael , Dempster Niall , Gathercole Laura , Cummins Carolyn , Tomlinson Jeremy

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of disease ranging from simple intrahepatic lipid accumulation to fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). 5β-reductase (AKR1D1) is a liver enzyme that catalyses a fundamental step in bile acid (BA) synthesis. Both BAs and BA intermediates are established as potent regulators of metabolic and proliferative phenotype. We have hypothesised that AKR1D1 plays a crucial regulatory role in NAFLD and HCC. Hu...